<DOC>
	<DOC>NCT00656084</DOC>
	<brief_summary>To determine the efficacy (response rate) produced by the combination of Gemzar, Novantrone, and Rituxan in relapsed or refractory MCL</brief_summary>
	<brief_title>Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Mantle-Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Stage III or IV, histologically confirmed relapsed or refractory MCL as reviewed by the SI Is CD20 positive (by immunohistochemistry or FACS) Is Cyclin D positive (by immunohistochemistry or FACS) Has received prior chemotherapy (required minimum of 1 prior therapies) Has received prior treatment with Rituxan Has an ECOG Performance Status (PS) 02 Is greater than or equal to 18 years of age Has appropriate laboratory values (please refer to protocol for specific laboratory values) If a history of cardiac disease is indicated, patient has an LVEF greater than or equal to 50% (MUGA) Has a negative serum pregnancy test within 7 days prior to registration (female patients of childbearing potential) If fertile, patient (male or female) has agreed to use an acceptable method of birth control to avoid pregnancy for the duration of the study and for a period of 2 months thereafter Has signed a Patient Informed Consent Form Has signed a Patient Authorization Form Has other lymphomas not classified as MCL Has had prior treatment with Gemzar and/or Novantrone A history of known hypersensitivity to Gemzar, Novantrone, Rituxan, or any component of these drugs Has a history of hypersensitivity to murinecell derived therapeutics Has a LVEF indicative of a cardiac condition (LVEF &lt; 50%) Is receiving concurrent immunotherapy Has evidence of CNS involvement Has a serious uncontrolled intercurrent medical or psychiatric illness, including serious infection Has a history of other malignancy within the last 5 years (except cured basal cell carcinoma of skin and carcinoma insitu of uterine cervix), which could affect the diagnosis or assessment of any of the study drugs Is a pregnant or nursing woman Is unable to comply with requirements of study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>